Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knopp Neurosciences Inc.

Division of Knopp Biosciences LLC
www.knoppneurosciences.com

Latest From Knopp Neurosciences Inc.

AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013

Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.

BioPharmaceutical Deals

Scientific Advances Increase Potential For Drugs To Treat ALS

New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.

BioPharmaceutical Clinical Trials

ALS Drug Development Gets FDA Hearing, Could See Push For Surrogate Markers

The ALS Association says it worked with FDA to seek a public forum in which ALS patients can present their perspective on benefit/risk in development of drugs for their condition.

BioPharmaceutical United States

Deals Of The Week: Pfizer/Halozyme, Celgene/Sutro Biopharma, Amgen/ImmunoGen

The week before Christmas proved to be an extraordinarily busy one for biopharmaceutical business development, highlighted by a Pfizer deal to enhance delivery of its biologics, an ALS research consortium led by Biogen Idec and the merger of two European companies, creating vaccine- and antibody-focused Valneva.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Knopp Biosciences LLC
  • Senior Management
  • Michael E Bozik, MD, Pres. & CEO
    Gregory T Hebrank, MD, EVP, Corp. Operations & Fin.
    Thomas Petzinger, Jr., EVP, Bus. Dev. & Public Affairs
    Dworetzky Steven, PhD, VP, Discovery Research
    Evan W Ingersoll, PhD, CDO & SVP, Dev. & Project Mgmt.
    Suresh Khemani, VP, Medical & Commercial Affairs
  • Contact Info
  • Knopp Neurosciences Inc.
    Phone: (412) 488-1776
    2100 Wharton St.
    Ste. 615
    Pittsburgh, PA 15203
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register